Set to start its Phase III trial for antibacterial candidate plazomicin this quarter, Achagoen Inc. filed for a $74.8 million initial public offering (IPO), which, along with anticipated funding from the Biomedical Advanced Research and Development Authority (BARDA), could take the firm through top-line data, expected in the first half of 2017.